Related Experiment Video

Updated: May 9, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Antiproliferative diarylpyrazole derivatives as dual inhibitors of the ERK pathway and COX-2

Mohammed I El-Gamal1, Hong Seok Choi, Kyung Ho Yoo

  • 1Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul, 130-650, Korea; Department of Biomolecular Science, University of Science and Technology, 113 Gwahangno, Yuseong-gu, Daejeon, 305-333, Korea; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, 35516, Egypt.

Chemical Biology & Drug Design
|July 10, 2013
PubMed

Insights

New 3,4-diarylpyrazole-1-carboxamide derivatives show potent anticancer activity. Compound 10o selectively targets melanoma by inhibiting cyclooxygenase-2 and the ERK pathway.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Developing novel anticancer agents is crucial for improving patient outcomes.
  • Targeting specific molecular pathways involved in cancer proliferation is a key strategy in drug discovery.

Purpose of the Study:

  • To design and synthesize novel 3,4-diarylpyrazole-1-carboxamide derivatives.
  • To evaluate the in vitro antiproliferative activity of these compounds against a panel of 60 cancer cell lines.
  • To investigate the inhibitory effects on cyclooxygenase (COX) isozymes and mitogen-activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK) pathways.

Main Methods:

  • Synthesis of 3,4-diarylpyrazole-1-carboxamide derivatives.
  • In vitro antiproliferative assays against 60 cancer cell lines at the National Cancer Institute (NCI).
  • Determination of IC50 values for the most active compounds.
  • Enzyme inhibition assays for COX isozymes.
  • Western blot analysis for MEK and ERK kinase inhibition.

Main Results:

  • Four compounds (9a, 9l, 9n, 10o) demonstrated significant antiproliferative activity.
  • Compound 10o exhibited selectivity towards a melanoma cell line subpanel.
  • Compound 10o showed selective inhibition of cyclooxygenase-2 (COX-2).
  • Compound 10o demonstrated inhibition of the ERK pathway.

Conclusions:

  • 3,4-diarylpyrazole-1-carboxamide derivatives represent a promising class of anticancer agents.
  • Compound 10o's selective activity against melanoma may be linked to its dual inhibition of COX-2 and the ERK pathway.
  • Further investigation into compound 10o as a potential therapeutic agent for melanoma is warranted.
Keywords:
3,4-diarylpyrazole-1-carboxamideERK pathwayanticancercyclooxygenase-2pyrazolevicinal diaryl heterocycle

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...